Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTSBVFO)

• DTT Name: Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DTT Info
• Gene Name: DYRK1A

Molecule-Related Drug & Molecule List

43 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzimidazole	DM1IZA7	Cytomegalovirus Disease	1D82	Patented	[1]
Harmine	DMPA5WD	Discovery agent	N.A.	Patented	[1]
PMID28766366-Compound-Scheme11	DMBN3X4	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme12-1	DMMJ5SN	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme12-2	DM3BA1L	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme12-3	DM4V3AY	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme12-4	DM5BG6L	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme13INDY	DMLQCYV	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme14BINDY	DMBQ0RN	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme15-1	DMVG275	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme15-2	DMU8ENF	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme15-3	DMA423P	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme16DMAT	DMQ5UEA	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme18	DMBQ21J	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme1WO2011135259	DMHIUWX	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme21Left	DMWTRUK	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme21Right	DMF3X40	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme23MPPDerivatives	DMRLSKV	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole	DMBWAV7	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme24Paprotrain	DMNKRSZ	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme25-2	DM7OGWH	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme25-3	DMGVT5Y	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme25-4	DMOD9BY	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme27LeucettamineB	DM3Q1FT	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme27LeucettineL41	DMLX26R	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme27LeucettineL41derivatives	DMPVZ6W	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme2WO2012/098065bottom	DMO4Q95	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme2WO2012/098065upper	DMVJDRI	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme4Bottom	DMDXIU9	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme4Upper	DMPH4JV	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme5	DMO6KZ5	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines	DMJOG3W	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme7WO2012/098070bottom	DMQV6R0	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme7WO2012/098070upper	DMGAQR5	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme8NCGC-00010037	DMSX09A	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme8NCGC-00185981	DMDUSN5	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme8NCGC-00189310	DMUWZD9	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme9EHT1610	DMMZGC8	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme9EHT3356	DMVBPML	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme9EHT5372	DM0O18N	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme9EHT6840	DMVY6PX	N. A.	N. A.	Patented	[1]
PMID28766366-Compound-Scheme9EHT9851	DM7RPKM	N. A.	N. A.	Patented	[1]
TG003	DMP4HR2	Discovery agent	N.A.	Patented	[1]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KH-CB19	DMSOB3U	Discovery agent	N.A.	Investigative	[2]
leucettine L41	DMBYND6	Discovery agent	N.A.	Investigative	[3]
ML315	DMNOREK	Discovery agent	N.A.	Investigative	[4]
PMID23642479C17	DM4JWMA	Discovery agent	N.A.	Investigative	[4]
PMID24900699C68	DM2V4MJ	Discovery agent	N.A.	Investigative	[5]
WO2013026806C72	DM21WOP	Discovery agent	N.A.	Investigative	[6]

References

• [1] Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
• [2] Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
• [3] Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
• [4] Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
• [5] Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2009).